ERBB2 and breast carcinoma: This study aimed to evaluate clinicopathological factors associated with NAT sensitivity and to develop a predictive model.<h4>Methods</h4>This retrospective study included 13,004 HER2-positive breast cancer patients from the National Cancer Database (2010-2022) who received neoadjuvant chemotherapy plus HER2-targeted therapy.